Company intelligence / Profile preview

Cubist Pharmaceuticals, Inc.

Lexington, Massachusetts, United Statesmerck.com ↗

Ownership: Private
Employees: ~1000
Development stage: Commercial

Overview

Cubist was a leader in antibiotics with marketed products and late-stage pipeline medicines. Their lead product CUBICIN was the only approved once-a-day therapy for both Staphylococcus aureus bacteremia and complicated skin and skin structure infections. ZERBAXA was pending FDA approval at the time of acquisition for Gram-positive and Gram-negative multi-drug resistant infections.

Therapeutic areas: GastroenterologyInfectious Diseases
Modalities: Antibioticssmall molecules
Industry: Biotech

Drug pipeline

2 assets

daptomycin

Commercial

Indications: S. aureus bacteremia, Complicated skin and skin structure infections

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Cubist Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cubist Pharmaceuticals, Inc..

Explore the full profile